EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) noticed unusually giant choices buying and selling exercise on Thursday. Inventory traders acquired 4,168 put choices on the inventory. This represents a rise of 53% in comparison with the common quantity of 2,720 put choices.
Analysts Set New Value Targets
EYPT has been the subject of a quantity of analysis analyst experiences. Capital One Monetary reiterated an “obese” ranking on shares of EyePoint Pharmaceuticals in a report on Friday, February sixteenth. JPMorgan Chase & Co. assumed protection on shares of EyePoint Pharmaceuticals in a analysis word on Monday, January twenty second. They issued an “obese” ranking and a $35.00 goal worth on the inventory. Mizuho raised their goal worth on shares of EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the corporate a “purchase” ranking in a analysis word on Friday, February sixteenth. Lastly, HC Wainwright minimize their goal worth on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “purchase” ranking on the inventory in a analysis word on Tuesday, January sixteenth. One analysis analyst has rated the inventory with a maintain ranking and 7 have issued a purchase ranking to the corporate’s inventory. In accordance with information from MarketBeat.com, the corporate at the moment has a median ranking of “Average Purchase” and a consensus worth goal of $33.86.
Get Our Latest Stock Analysis on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Trading Up 0.3 %
EYPT stock traded up $0.07 throughout mid-day buying and selling on Thursday, hitting $23.42. 706,623 shares of the corporate have been exchanged, in comparison with its common quantity of 1,065,349. The corporate has a market capitalization of $1.17 billion, a PE ratio of -12.87 and a beta of 1.66. EyePoint Pharmaceuticals has a twelve month low of $2.21 and a twelve month excessive of $30.99. The agency has a fifty day easy shifting common of $25.69 and a 200 day easy shifting common of $16.62.
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) final introduced its quarterly earnings information on Thursday, March seventh. The corporate reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.27. The corporate had income of $14.03 million in the course of the quarter, in comparison with analyst estimates of $8.71 million. EyePoint Pharmaceuticals had a detrimental internet margin of 153.84% and a detrimental return on fairness of 61.48%. Throughout the identical interval final 12 months, the enterprise earned ($0.61) EPS. As a gaggle, sell-side analysts anticipate that EyePoint Pharmaceuticals will submit -1.73 earnings per share for the present 12 months.
Insiders Place Their Bets
In different EyePoint Pharmaceuticals information, Director Ye Liu bought 1,910,500 shares of the corporate’s inventory in a transaction dated Thursday, January eleventh. The shares have been bought at a median worth of $19.45, for a complete worth of $37,159,225.00. Following the sale, the director now owns 100,221 shares of the corporate’s inventory, valued at $1,949,298.45. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which will be accessed by means of the SEC website. In associated information, Director Ye Liu bought 1,910,500 shares of the corporate’s inventory in a transaction that occurred on Thursday, January eleventh. The shares have been bought at a median worth of $19.45, for a complete transaction of $37,159,225.00. Following the transaction, the director now owns 100,221 shares of the corporate’s inventory, valued at $1,949,298.45. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which is accessible by means of this link. Additionally, insider Dario A. Paggiarino bought 22,913 shares of the corporate’s inventory in a transaction that occurred on Monday, January eighth. The shares have been bought at a median worth of $21.13, for a complete transaction of $484,151.69. Following the transaction, the insider now immediately owns 36,505 shares within the firm, valued at roughly $771,350.65. The disclosure for this sale will be discovered here. Over the past three months, insiders have bought 1,989,582 shares of firm inventory value $39,080,886. 13.05% of the inventory is owned by firm insiders.
Institutional Inflows and Outflows
Hedge funds and different institutional traders have not too long ago modified their holdings of the enterprise. FNY Funding Advisers LLC acquired a brand new place in shares of EyePoint Pharmaceuticals within the 4th quarter valued at about $27,000. Toth Monetary Advisory Corp boosted its holdings in shares of EyePoint Pharmaceuticals by 250.0% within the third quarter. Toth Monetary Advisory Corp now owns 3,500 shares of the corporate’s inventory valued at $28,000 after shopping for a further 2,500 shares in the course of the interval. US Bancorp DE acquired a brand new place in shares of EyePoint Pharmaceuticals within the 4th quarter valued at about $85,000. China Common Asset Administration Co. Ltd. acquired a brand new place in shares of EyePoint Pharmaceuticals within the 4th quarter valued at about $94,000. Lastly, Tower Analysis Capital LLC TRC boosted its holdings in shares of EyePoint Pharmaceuticals by 99.3% within the third quarter. Tower Analysis Capital LLC TRC now owns 4,605 shares of the corporate’s inventory valued at $37,000 after shopping for a further 2,294 shares in the course of the interval. 99.41% of the inventory is owned by institutional traders and hedge funds.
EyePoint Pharmaceuticals Firm Profile
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical firm, engages in growing and commercializing therapeutics to enhance the lives of sufferers with critical retinal ailments. The corporate’s pipeline leverages its proprietary bioerodible Durasert E expertise for sustained intraocular drug supply.
Featured Tales
Earlier than you take into account EyePoint Pharmaceuticals, you will need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and EyePoint Pharmaceuticals wasn’t on the listing.
Whereas EyePoint Pharmaceuticals at the moment has a “Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
Click on the hyperlink under and we’ll ship you MarketBeat’s listing of seven shares and why their long-term outlooks are very promising.
EyePoint Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:EYPT) www.marketbeat.com 2024-03-21 23:41:50
Source link